Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00495) | |||||
---|---|---|---|---|---|
Name |
Osimertinib
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
osimertinib; AZD-9291; 1421373-65-0; AZD9291; Mereletinib; AZD 9291; Tagrisso; UNII-3C06JJ0Z2O; Osimertinib free base; N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide; 3C06JJ0Z2O; N-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide; 1421373-65-0 (free base); N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; Mereletinib [INN]; Osimertinib [USAN]; osimertinibum; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)acrylamide; Tube720; Osimertinib; AZD 9291; Osimertinib; AZD-9291; mereletinib (obsolete INN); AZD-9291 FREE BASE; GTPL7719; CHEMBL3353410; SCHEMBL14660911; CHEBI:90943; AOB6268; EX-A314; MereletinibAZD-9291,Osimertinib; C28H33N7O2; HMS3653E10; HMS3672M05; BCP08626; ABP001123; BDBM50029668; MFCD27988062; NSC779217; NSC781254; NSC800812; ZINC98023177; AKOS025290756; CCG-264683; CS-2018; DB09330; NSC-779217; NSC-781254; NSC-800812; SB22952; NCGC00378622-03; NCGC00378622-04; NCGC00378622-10; 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-; AC-29019; AK170511; AS-16943; HY-15772; QC-11454; SW219863-1; Q21506464; 1143020-91-0; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Lung cancer | ICD-11: 2C25 | [1] | ||
PubChem CID | |||||
Formula |
C28H33N7O2
|
||||
Canonical SMILES |
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
|
||||
InChI |
1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)
|
||||
InChIKey |
DUYJMQONPNNFPI-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=71496458"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 499.6 | Topological Polar Surface Area | 87.6 | |
XlogP | 3.7 | Complexity | 752 | ||
Heavy Atom Count | 37 | Rotatable Bond Count | 10 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Osimertinib 40 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Talc; Titanium dioxide; Polyethylene glycol 3350; Polyvinyl alcohol; Cellulose, microcrystalline; Hydroxypropyl cellulose, low substituted
|
|||||
Dosage Form | Oral Tablet | |||||
Company | AstraZeneca | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Osimertinib 80 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Mannitol; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Talc; Titanium dioxide; Polyethylene glycol 3350; Polyvinyl alcohol; Cellulose, microcrystalline; Hydroxypropyl cellulose, low substituted
|
|||||
Dosage Form | Oral Tablet | |||||
Company | AstraZeneca | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Osimertinib Mesylate eq 40mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Mannitol; Microcrystalline Cellulose; Low-Substituted Hydroxypropyl Cellulose; Sodium Stearyl Fumarate; Polyvinyl Alcohol; Titanium Dioxide; Macrogol 3350; Talc; Ferric Oxide Yellow; Ferric Oxide Red; Ferric Oxide Black
|
|||||
Dosage Form | Tablet | |||||
Company | Astrazeneca | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Hydroxypropyl cellulose | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) | [4] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Osimertinib Mesylate eq 80mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Mannitol; Microcrystalline Cellulose; Low-Substituted Hydroxypropyl Cellulose; Sodium Stearyl Fumarate; Polyvinyl Alcohol; Titanium Dioxide; Macrogol 3350; Talc; Ferric Oxide Yellow; Ferric Oxide Red; Ferric Oxide Black
|
|||||
Dosage Form | Tablet | |||||
Company | Astrazeneca | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [3] | |||
Hydroxypropyl cellulose | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 89.5 uM) | [4] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [4] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.